Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane ...
Novel oral agent nerandomilast slowed progression of idiopathic pulmonary fibrosis (IPF), even atop background antifibrotic therapy, the phase III FIBRONEER-IPF trial showed. Forced vital capacity ...
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease characterized by the excessive accumulation of extracellular matrix components, leading to a gradual decline in lung ...
DLCO declined earliest, falling measurably about 10 years before the defined onset. By five years before onset, DLCO had already dropped to roughly 86.8% predicted; five years after onset, it had ...
Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, ...
The top 5 idiopathic pulmonary fibrosis (IPF) articles of 2024 explored topics like the effect of oxygen therapy on health care costs and mortality; delayed diagnoses leading to worse outcomes; new ...
A recent study from China has reported that Cordyceps sinensis (CS), a traditional Chinese medicinal fungus, can ameliorate idiopathic pulmonary fibrosis (IPF) in mice by inhibiting ...
(left) The absolute change in FVC ± 95% CI. (center) The absolute change in FVC ± 95% CI ANCOVA model with multiple imputation assuming missing at random (MAR). (right) Changes in FVC ± 95% CI after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results